Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq

• Published in: Virchows Archiv : an international journal of pathology 2021-03, Vol.478 (3), p.569-579
• Main Authors: Takashima, Tsuyoshi, Sakamoto, Naoya, Murai, Junko, Taniyama, Daiki, Honma, Ririno, Ukai, Shoichi, Maruyama, Ryota, Kuraoka, Kazuya, Rajapakse, Vinodh N., Pommier, Yves, Yasui, Wataru
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - therapeutic use; Biomarkers; Biomarkers, Tumor - analysis; Biomarkers, Tumor - genetics; Carboplatin; Cell Line, Tumor; Cisplatin; Clinical Decision-Making; Cytarabine; Damage; Databases, Genetic; Deoxyribonucleic acid; DNA; DNA Damage; DNA helicase; Doxorubicin; Drug Resistance, Neoplasm; Drugs; Etoposide; Female; Gemcitabine; Gene expression; Genomes; Humans; Immune system; Immunohistochemistry; Immunosuppressive agents; Inhibitors; Lymphocytes; Lymphocytes B; Lymphocytes T; Macrophages; Male; Medicine; Medicine & Public Health; Neoplasms - drug therapy; Neoplasms - enzymology; Neoplasms - genetics; Neoplasms - pathology; Nuclear Proteins - analysis; Nuclear Proteins - genetics; Organs; Original Article; Pathology; Platinum; Predictive Value of Tests; Quality in Pathology; Replication; Reproducibility of Results; Ribonucleic acid; RNA; RNA helicase; RNA-Seq; Tumorigenesis; Tumors
• ISSN: 0945-6317; 1432-2307
• DOI: 10.1007/s00428-020-02840-6

DNA-damaging agents include first-line drugs such as platinum (cisplatin, carboplatin), topoisomerase inhibitors (etoposide, doxorubicin), and replication inhibitors (cytarabine, gemcitabine). Despite their wide and long usage, there is no clinically available biomarker to predict responses to these drugs. Schlafen 11 (SLFN11), a putative DNA/RNA helicase, recently emerged as a dominant determinant of sensitivity to these drugs by enforcing the replication block in response to DNA damage. Since the clinical importance of SLFN11 is implicated, a comprehensive analysis of SLFN11 expression across human organs will provide a practical resource to develop the utility of SLFN11 in the clinic. In this study, we established a scoring system of SLFN11 expression by immunohistochemistry (IHC) and assessed SLFN11 expression in ~ 700 malignant as well as the adjacent non-tumor tissues across 16 major human adult organs. We found that the SLFN11 expression is tissue specific and varies during tumorigenesis. Although The Cancer Genome Atlas (TCGA) is a prevailing tool to assess gene expression in various malignant and normal tissues, our IHC data exhibited obvious discrepancy from the TCGA data in several organs. Importantly, SLFN11-negative tumors, potentially non-responders to DNA-damaging agents, were largely overrated in TCGA because TCGA samples are a mixture of infiltrating immune cells, including T cells, B cells, and macrophages, which have strong SLFN11 expression. Thus, our study reveals the significance of immunohistochemical procedures for evaluating expression of SLFN11 in patient samples and provides a robust resource of SLFN11 expression across adult human organs.